Choose Your language:
- Testimonials
-
great service thanks
- andrew
Read more »
Our billing is certified by:
- News
-
- FDA approved Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years.
- Considering the information of three randomized, multicenter, double, blind clinical studies and a retrospective analysis of the medical documentation, FDA approved on October 7, 2011 Tadalafil medication for the treatment of erectile dysfunction accompanied with primary and secondary symptoms of benign prostatic hyperplasia (BPH) in men above 45 years
- The forming, development and monitoring of the pharmaceutical market in USA in September 2011
- In spite of low rates and stagnation of industrial development, the pharmaceutical market shows a dynamical growth
- Sildenafil citrate and pulmonary arterial hypertension
- Pulmonary arterial hypertension Definition “pulmonary arterial hypertension” is related to a group of diseases characterized by: - Progressive increase in pulmonary vascular resistance; - Reduction in pulmonary bloodflow; - High pulmonary artery pressure; - Contractility of the heart right ventricle; - Right ventricular failure
- Fruit and vegetables do not reduce overall cancer risk, review concludes
- Eating lots of fruit and vegetables will do little to reduce your risk of developing cancer, according to a review of a decade of research involving more than a million people
- Common painkillers could be linked to male reproductive disorder
- The use of mild painkillers, such as paracetamol, in pregnancy – previously considered harmless to the baby in the womb – could be a major factor in the rise of male reproductive disorders, according to a study
-
- Watson confirms filing of ANDA for generic version of Lo Loestrin Fe with FDA - Pharmaceutical Business Review
- Watson confirms filing of ANDA for generic version of Lo Loestrin Fe with FDAPharmaceutical Business ReviewWatson Pharmaceuticals has confirmed the filing of ANDA with FDA by Watson Laboratories seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets, 1mg/0
- Watson Confirms Lo Loestrin® Fe Patent Challenge - MarketWatch (press release)
- Watson Confirms Lo Loestrin® Fe Patent ChallengeMarketWatch (press release)
- Lilly, Jaguar Land Rover, Viacom: Intellectual Property - BusinessWeek
- Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyBusinessWeekLo Loestrin Fe contains the active ingredients norethindrone acetate and ethinyl estradiol
- Lilly, Jaguar Land Rover, Viacom: Intellectual Property - Bloomberg
- Lilly, Jaguar Land Rover, Viacom: Intellectual PropertyBloombergLo Loestrin Fe contains the active ingredients norethindrone acetate and ethinyl estradiol
- Perrigo Announces FDA Final Approval and Launch of OTC Lansoprazole; Watson ... - BioMedReports (subscription)
- Perrigo Announces FDA Final Approval and Launch of OTC Lansoprazole; Watson
